Skip to main content

Update on Abciximab Readministration During Percutaneous Coronary Interventions.

Publication ,  Journal Article
Madan, M; Tcheng, JE
Published in: Curr Interv Cardiol Rep
August 2000

Abciximab is a monoclonal antibody fragment that blocks the platelet glycoprotein IIb/IIIa receptor and is increasingly used as an adjunct to percutaneous coronary intervention. Because some patients will return for additional revascularization procedures, it is anticipated that abciximab retreatment may be necessary. There exists at least the theoretic potential for immunologic reactions and diminished efficacy upon re-exposure to abciximab. The limited data available regarding abciximab retreatment suggests that readministration is as safe and effective as first-time treatment, provided certain precautions are taken. This review summarizes the available clinical data and provides suggestions for safe abciximab readministration.

Duke Scholars

Published In

Curr Interv Cardiol Rep

ISSN

1523-3839

Publication Date

August 2000

Volume

2

Issue

3

Start / End Page

244 / 249

Location

United States
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Madan, M., & Tcheng, J. E. (2000). Update on Abciximab Readministration During Percutaneous Coronary Interventions. Curr Interv Cardiol Rep, 2(3), 244–249.
Madan, M., and J. E. Tcheng. “Update on Abciximab Readministration During Percutaneous Coronary Interventions.Curr Interv Cardiol Rep 2, no. 3 (August 2000): 244–49.
Madan M, Tcheng JE. Update on Abciximab Readministration During Percutaneous Coronary Interventions. Curr Interv Cardiol Rep. 2000 Aug;2(3):244–9.
Madan, M., and J. E. Tcheng. “Update on Abciximab Readministration During Percutaneous Coronary Interventions.Curr Interv Cardiol Rep, vol. 2, no. 3, Aug. 2000, pp. 244–49.
Madan M, Tcheng JE. Update on Abciximab Readministration During Percutaneous Coronary Interventions. Curr Interv Cardiol Rep. 2000 Aug;2(3):244–249.

Published In

Curr Interv Cardiol Rep

ISSN

1523-3839

Publication Date

August 2000

Volume

2

Issue

3

Start / End Page

244 / 249

Location

United States